Latest Glucagon Stories
DALLAS, March 16, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Hypoglycemia - Pipeline Review, H1 2015" therapeutic market research report provides an overview of the
Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., June 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results
FREMONT, Calif., May 19, 2014 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery
LAS VEGAS, May 16, 2014 /PRNewswire/ -- Results from the SCALE(TM) Obesity and Pre-diabetes phase 3a trial will be presented on May 16, 2014, for the first time at the 23rd Annual Congress of
Greater than 2 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., May 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
An international team led by scientists at The Scripps Research Institute (TSRI) has determined and analyzed the three-dimensional atomic structure of the human glucagon receptor.
Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...
- an ornament or knob in the shape of a flower